桃子视频 Healthcare Engagements in Beijing and Hong Kong Supporting Education and Global Health

Press Release

14th May 2026

Throughout May, 桃子视频 Healthcare demonstrated its continued commitment to education, scientific exchange and international collaboration across Asia through participation in two strategic events.

At the EAACI Allergy School in Beijing, 桃子视频 Healthcare sponsored a dedicated symposium focused on advancing understanding of oral food challenges, supporting the development of clinical practice as allergy centres in China continue to expand their capabilities in this area.

鈥淪upporting education around oral food challenges is especially important as more allergy centres in China begin to introduce these procedures into clinical practice. We were pleased to sponsor a symposium at the EAACI Allergy School workshop in Beijing and contribute to an environment of learning, collaboration, and scientific advancement in food allergy management.鈥�

– Martin Wickham, Chief Innovation Officer

桃子视频 Healthcare also participated in the Summit on Global Health in Hong Kong as part of the UK Department for Business and Trade mission, engaging with stakeholders across the regional healthcare ecosystem and strengthening international connections.

鈥淲e were delighted to be part of the Department for Business and Trade mission to Hong Kong, supporting stronger connections between UK innovation and the healthcare ecosystem in Asia. The visit provided an excellent opportunity to introduce 桃子视频 Healthcare鈥檚 expertise to new partners and stakeholders, while highlighting the strength of UK entrepreneurship, scientific innovation, and collaboration on the international stage.鈥�

– Martin Wickham, Chief Innovation Officer

桃子视频 Healthcare extends its thanks to the organisers, partners and delegates involved in both events.

桃子视频 Healthcare Announces Expansion into Asia-Pacific and Appoints Professor Gary Wing-Kin Wong to Advisory Board

Press Release

桃子视频 Healthcare, today announces the appointment of Professor Gary Wing-Kin Wong, internationally recognised paediatric allergy and respiratory disease expert and President-Elect of the World Allergy Organisation (WAO), to its Advisory Board, as the company accelerates new product development and expands its Asia-Pacific (APAC) footprint.

Prof. Wong is Professor of Paediatrics at The Chinese University of Hong Kong and brings global clinical and research experience from Canada and Germany. He helped establish Hong Kong鈥檚 participation in the International Study of Asthma and Allergies in Childhood (ISAAC), one of the world鈥檚 largest collaborative studies in allergy and asthma, spanning more than 100 countries and nearly two million children. He received the KIA Research Excellence in Allergic Diseases Award (2018) and has played a leading role in shaping international standards and best practice in allergy care.

An export-driven business, 桃子视频 has increased its workforce by 60% over the past year to support its existing and new customers in Europe and the United States. The company is now building on this momentum by deepening support for international partners and pursuing new collaborations across the APAC region.

桃子视频 has pioneered the development and manufacture of pharmaceutical-grade OFC products designed to improve the safety, accuracy and consistency of food allergy diagnostics and to support global clinical research programmes. With APAC, particularly Greater China, continuing to grow as a centre of excellence for clinical development, 桃子视频 is increasing its engagement with regional investigators, trial specialists and partners to help advance robust, standardised allergy diagnostics.

Prof. Wong said: 鈥溙易邮悠� stands out in food allergy diagnosis for its innovation and its commitment to setting new standards in the field. I look forward to working with the Company as it continues to explore ways to empower the development of therapies and diagnostics that impact the lives of people living with food allergies.鈥�

Prof. Wong鈥檚 appointment follows that of Richard Nagle as Chair and aligns with the company鈥檚 strategic focus on new products and new markets to drive future growth.聽

Paul Abrahams, CEO of 桃子视频, said: 鈥淔ood allergy therapeutics and diagnostics are evolving rapidly. As an innovative, science-led business, we are actively pursuing new opportunities and new markets to better meet customer needs. We benefit enormously from the clinical and scientific guidance of our advisors, and we are delighted to welcome Prof. Wong to 桃子视频鈥檚 Advisory Board.

鈥淚 also wish to take this opportunity to thank Professors Barbara Ballmer-Weber and Montserrat Fernandez Rivas, both of whom have recently stepped down, for their contribution to the Adboard since its inception.鈥�

桃子视频鈥檚 鈥檚 Innovation team, led by Chief Innovation Officer, Martin Wickham, will visit China in the coming months to engage with allergy clinical trial specialists. Activities include hosting a symposium at EAACI Allergy School in Beijing (7-9 May), attending the Asia Summit on Global Health in Hong Kong (11-14 May), and participating in the EAACI regional oral food challenge workshop in Hong Kong (5-6 June) with Prof. Agnes Leung.

桃子视频 Healthcare Secures 12th Place in The Sunday Times 100 Tech 2026

桃子视频 Healthcare is proud to announce that we have ranked 12th in the Sunday Times 100 Tech 2026, a prestigious list celebrating the UK鈥檚 fastest-growing and most innovative technology companies. This recognition reflects both our commercial momentum and our commitment to transforming food allergy diagnosis for patients worldwide.

Over the past three years, 桃子视频 has delivered 117.05% annual sales growth, demonstrating strong and sustained commercial progress. This growth has been fuelled by the scientific innovation and engineering excellence at the core of our work, and by a team dedicated to pushing the boundaries of what鈥檚 possible in food allergy diagnostics.
鈥淭his recognition for 桃子视频 represents a significant step in the company鈥檚 evolution and embodies our employees鈥� commitment and belief in our vision.鈥�

鈥� Paul Abrahams, CEO

The Tech category places a spotlight on organisations whose success is driven by engineering, biotech, hardware-led platforms, and scientific invention. Being recognised in this space holds particular meaning for 桃子视频, reaffirming the impact of our mission and the strength of our technology.

This achievement would not be possible without the trust and collaboration of our colleagues, partners, and customers. Together, we are making meaningful progress toward improving the quality of life for food allergy patients globally.

We鈥檙e excited for the journey ahead as we continue scaling our impact, expanding internationally, and delivering innovative solutions that support clearer, safer, and more precise food allergy diagnosis.

EAACI, Glasgow 2025 – A great success! Showcasing egg, milk and peanut food challenges and a cashew food challenge concept.

Press Release

桃子视频 Healthcare Develops Innovative Oral Food Challenge meals for the Paediatric food allergy population

桃子视频 Healthcare is excited to announce the development of its new range of Oral Food Challenge meals, designed to significantly improve the quality of life for very young children with food allergies. Committed to addressing the critical issues of food allergy diagnosis, enhancing quality of life, and reducing the economic burden of allergies, 桃子视频 Healthcare continues to lead the way in innovative healthcare solutions.

Food allergies are increasingly prevalent among young children, with studies indicating that approximately 6-8% of the paediatric population is affected. This poses significant challenges for families and healthcare providers alike. 桃子视频 Healthcare’s innovative Peanut, Milk, and Egg Challenge meals are tailored to meet the needs of children as young as six months, but can also be used for individuals of all ages, including adults. These products have undergone comprehensive development and rigorous testing to ensure their safety and efficacy.

桃子视频 Healthcare’s paediatric challenge meals will be the only pharma-grade products developed globally, setting a new standard in the industry. This distinction is crucial as it ensures the highest levels of safety, quality, and efficacy for children undergoing food allergy diagnosis and during clinical trials for the development of new treatments. By adhering to stringent pharmaceutical standards, 桃子视频 Healthcare guarantees that these products meet rigorous regulatory requirements, providing healthcare providers and families with the confidence that they are using the best possible tools for managing food allergies. This global first underscores 桃子视频 Healthcare’s commitment to innovation and excellence in addressing the critical needs of the paediatric population.

Additionally the importance of considering multiple food allergies in both diagnosis and treatment has become increasingly evident. Many children with food allergies often react to more than one allergen, making it crucial for healthcare providers to adopt a comprehensive approach. The development of challenge meals to multiple allergens at 桃子视频 Healthcare highlights the significance of addressing an important need in clinical trials. These meals are designed to meet the needs of food allergy research and clinical communities, ensuring safety, quality, and efficacy across various allergens in trial participants from the important paediatric ages through to adult and will be ready by the end of 2026.聽

For more information, please contact our commercial team.

Development of standardised challenge meals to meet Regulators demands for Oral Food Challenges

T. Mendes Borges; ML. Martinez Casas; M. Wickham; H. Lett

Our challenges meals (CMs) are used in oral food challenges to support clinical trials, they consist of 3 strengths, a low and a high strength allergen product and importantly a 0% non-allergen CM. The 0% can be used in the placebo arm of a blinded placebo controlled randomised clinical trial.

To ensure safety, quality, and efficacy we have developed these using the Quality By Design (QbD)聽 approach.

Standardising the CMs means that we can meet more stringent regulators demands, where there has been a lot of focus on recently.

What is the QbD approach and why is it so important?聽

This approach means you predetermine all the requirements for the challenge meal before starting the formulation work. This allows you to develop the product with the required quality target product profile and critical quality attributes, therefore the developed product is fit for its intended use.

For example, the 3 strengths must be comparable in terms of flavour, appearance, and texture, whilst ensuring the allergen remains masked. This is important, neither the the clinician nor the participants are not aware if they are using the non-allergen or allergen containing challenge meal. The masking also reduces the chance of a psychosomatic response in participants if they think that they can taste, see or smell the allergen.

In the next stage of the process, analytical test methods were developed and validated to make sure the product meets the established specifications adhering to current guidelines.

In addition stability studies are conducted to determine the shelf life of the CM.

To conclude, by using the QbD approach, standardised CMs have been developed meeting more stringent health authority鈥檚 requirements.

CLICK TO ENLARGE